Scholars@Duke
Daniel Bryce Landi

Daniel Bryce Landi

Associate Professor of Pediatrics
Pediatrics, Hematology-Oncology
daniel.landi@duke.edu
Box 102382, Durham, NC 27710
330 Trent Drive, Room 390, Durham, NC 27710

Scholarly Works - Conferences

Outcomes and immune response after peptide vaccination targeting human cytomegalovirus antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma

Conference Journal of Clinical Oncology · January 1, 2024 Background: The human cytomegalovirus (CMV) antigen pp65 is ubiquitously expressed in high-grade glioma (HGG) and medulloblastoma but not in adjacent brain. The primary objective of this first-in-human phase I trial (NCT03299309) was to assess the safety a ... Full text Cite

A phase 1 trial of D2C7-it in combination with an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convectionenhanced delivery for adult patients with recurrent malignant glioma (MG).

Conference JOURNAL OF CLINICAL ONCOLOGY · 2022 Background: D2C7 immunotoxin (D2C7-IT) is a dual-specific recombinant immunotoxin comprising an EGFR wild-type and mutant-specific (EGFRvIII) monoclonal antibody (Ab) fragment and a genetically engineered form of the Pseudomonas exotoxin. When injected dir ... Full text Link to item Cite

QOLP-28. COMPARING KNOWLEDGE OF AND BELIEFS ABOUT PALLIATIVE CARE AMONG NEURO-ONCOLOGY PATIENTS, CAREGIVERS, PROVIDERS AND A NATIONALLY-REPRESENTATIVE U.S. SAMPLE

Conference Neuro-Oncology · November 12, 2021 AbstractINTRODUCTIONThere is increasing recognition that palliative care (PC) can benefit patients with advanced cancers. However, ear ... Full text Open Access Link to item Cite

INNV-20. RADIOGRAPHIC RESPONSE AND SEIZURE CONTROL IN IDH1 MUTANT GLIOMA PATIENTS USING IVOSIDENIB

Conference Neuro-Oncology · November 12, 2021 AbstractIsocitrate dehydrogenase 1 (IDH1) is commonly mutated in grade II-III gliomas, and the mutant enzyme leads to the production of the oncometabolite 2-hydroxyglutarate (2-HG). 2-HG is responsible for t ... Full text Open Access Link to item Cite

QOLP-10. A LONGITUDINAL OBSERVATIONAL STUDY OF EXERCISE BEHAVIOR IN GLIOBLASTOMA PATIENTS TREATED WITH TUMOR-TREATING FIELDS

Conference Neuro-Oncology · November 12, 2021 AbstractGlioblastoma (GBM) patients can use tumor-treating fields (TTFs) with adjuvant temozolomide (TMZ) to treat their disease. TTFs involve wearing transfixed transducers to the shaved scalp, and the tran ... Full text Open Access Link to item Cite

INNV-31. NEURO-ONCOLOGY OUTPATIENT SATISFACTION IS MAINTAINED IN THE ERA OF COVID-19 TELEMEDICINE

Conference Neuro-Oncology · November 12, 2021 AbstractINTRODUCTIONThe use of telemedicine increased during the COVID-19 pandemic. However, the impact on patient satisfaction in the ... Full text Open Access Cite

CTIM-10. REPRODUCIBILITY OF CLINICAL TRIALS USING CMV-TARGETED DENDRITIC CELL VACCINES IN PATIENTS WITH GLIOBLASTOMA

Conference Neuro-Oncology · November 12, 2021 AbstractINTRODUCTIONVaccination with dendritic cells (DCs) fares poorly in primary and recurrent glioblastoma (GBM). Moreover, GBM vac ... Full text Open Access Link to item Cite

IMMU-26. SAFETY AND EFFICACY OF PVSRIPO IN RECURRENT GLIOBLASTOMA: LONG-TERM FOLLOW-UP AND INITIAL MULTICENTER RESULTS

Conference Neuro-Oncology · November 12, 2021 AbstractBACKGROUNDRecurrent glioblastoma (rGBM) is rapidly fatal (median overall survival [mOS] of ~9 months; OS at 12 months [OS12] & ... Full text Cite

EXTH-59. GENERATION OF A THIRD GENERATION CAR T CELL THAT SIMULTANEOUSLY TARGETS WILDTYPE EGFR AND ITS MUTANT ISOFORM EGFRVIII FOR TREATMENT OF GLIOBLASTOMA

Conference Neuro-Oncology · November 12, 2021 AbstractGlioblastoma (GBM) is the most aggressive primary brain cancer with a median survival of less than 16 months. This dire prognosis signifies the urgent need for improved treatment options, such as imm ... Full text Cite

CTIM-18. LUMINOS-101: INITIAL SAFETY AND TOLERABILITY OF PVSRIPO AND PEMBROLIZUMAB COMBINATION THERAPY IN RECURRENT GLIOBLASTOMA

Conference Neuro-Oncology · November 12, 2021 AbstractBACKGROUNDRecurrent glioblastoma (rGBM) is rapidly fatal with current therapies. PVSRIPO is an intratumoral immunotherapy targ ... Full text Cite

EPCT-01. A NOVEL PEPTIDE VACCINE DIRECTED TO CMV PP65 FOR TREATMENT OF RECURRENT MALIGNANT GLIOMA AND MEDULLOBLASTOMA IN CHILDREN AND YOUNG ADULTS: PRELIMINARY RESULTS OF A PHASE I TRIAL

Conference Neuro-Oncology · June 1, 2021 AbstractIntroductionThe cytomegalovirus (CMV) antigen, pp65, is ubiquitously expressed in malignant glioma and medulloblastoma but not ... Full text Link to item Cite

LGG-08. TREATMENT OUTCOMES AND TOLERABILITY OF TRAMETINIB IN PROGRESSIVE CIRCUMSCRIBED LOW-GRADE GLIOMAS

Conference Neuro-Oncology · June 1, 2021 AbstractCircumscribed low-grade gliomas comprise roughly one-third of pediatric CNS tumors. Most of these tumors are caused by activating mutations in the mitogen-activated protein kinase (MAPK) pathway. Dru ... Full text Cite

LUMINOS-101: Phase 2 study of PVSRIPO with pembrolizumab in recurrent glioblastoma.

Conference Journal of Clinical Oncology · May 20, 2021 TPS2065 Background: The prognosis for patients (pts) with recurrent (r) glioblastoma (GBM) is poor, with no highly effective approved therapies. Treatment failure may result from poor penetration of drugs through the blood-brain ... Full text Cite

FIREFLY-1: A phase 2 study of the pan-RAF inhibitor DAY101 in pediatric patients with low-grade glioma.

Conference Journal of Clinical Oncology · May 20, 2021 TPS10056 Background: The mitogen-activated protein kinase (MAPK) signaling pathway is an essential pathway that regulates key cell functions such as growth, survival, and differentiation. Genomic alterations and dysregulation of ... Full text Cite

INNV-20. RADIOGRAPHIC RESPONSE AND SEIZURE CONTROL IN IDH1 MUTANT GLIOMA PATIENTS USING IVOSIDENIB

Conference NEURO-ONCOLOGY · 2021 Isocitrate dehydrogenase 1 (IDH1) is commonly mutated in grade II-III gliomas, and the mutant enzyme leads to the production of the oncometabolite 2-hydroxyglutarate (2-HG). 2-HG is responsible for the gliomagenesis associated with these tumors and the pro ... Full text Link to item Cite

THER-05. GENETICALLY STABLE POLIOVIRUS VECTOR CARRYING H3.3K27M ANTIGEN FOR TREATMENT OF DIFFUSE MIDLINE GLIOMA BY INTRAMUSCULAR INJECTION

Conference Neuro-Oncology · December 4, 2020 AbstractBACKGROUNDH3 K27M-mutant diffuse midline glioma (DMG) is invariably lethal. Viruses naturally engage innate immunity, induce a ... Full text Cite

EPID-16. INTEGRATION OF EHR AND CANCER REGISTRY DATA TO CONSTRUCT A PEDIATRIC NEURO-ONCOLOGY SURVIVORSHIP COHORT AND IMPROVE LONG-TERM FOLLOW-UP CARE

Conference Neuro-Oncology · December 4, 2020 AbstractBACKGROUNDPediatric neuro-oncology (PNO) survivors suffer long-term physical and neurocognitive morbidity. Comprehensive care ... Full text Cite

MBCL-25. PILOT STUDY OF A SURGERY AND CHEMOTHERAPY-ONLY APPROACH IN THE UPFRONT THERAPY OF CHILDREN WITH WNT-POSITIVE STANDARD RISK MEDULLOBLASTOMA: UPDATED OUTCOMES

Conference Neuro-Oncology · December 4, 2020 AbstractBACKGROUNDWnt+ medulloblastoma (WPM) is a favorable subtype with EFS > 90% when treating postoperatively with craniospi ... Full text Cite

EPCT-13. CMV PP65 RNA-PULSED DENDRITIC CELL VACCINES FOR PEDIATRIC GLIOBLASTOMA AND MEDULLOBLASTOMA: PHASE I TRIAL RESULTS

Conference Neuro-Oncology · December 4, 2020 AbstractBACKGROUNDRecurrent medulloblastoma and malignant glioma are lethal tumors that are virtually incurable. The cytomegalovirus ( ... Full text Cite

CTIM-21. PEPTIDE VACCINE DIRECTED TO CMV pp65 FOR TREATMENT OF RECURRENT MALIGNANT GLIOMA AND MEDULLOBLASTOMA IN CHILDREN AND YOUNG ADULTS: PRELIMINARY RESULTS OF A PHASE I TRIAL

Conference Neuro-Oncology · November 9, 2020 AbstractINTRODUCTIONThe cytomegalovirus (CMV) antigen, pp65, is ubiquitously expressed in malignant glioma and medulloblastoma but not ... Full text Open Access Link to item Cite

BIOM-17. BRAF MUTATION IS AN EARLY EVENT IN THE EVOLUTION OF A SUBSET OF GLIOBLASTOMAS AND IS ASSOCIATED WITH INCREASED PD-L1 EXPRESSION

Conference Neuro-Oncology · November 9, 2020 AbstractINTRODUCTIONBRAF is a RAF-family kinase that regulates MAPK/ERK signaling. Activating BRAF mutations, including V600E, are com ... Full text Cite

CTIM-23. A PHASE 1 TRIAL OF D2C7-IT IN COMBINATION WITH ATEZOLIZUMAB IN RECURRENT WHO GRADE IV MALIGNANT GLIOMA (MG)

Conference Neuro-Oncology · November 9, 2020 AbstractBACKGROUNDD2C7 immunotoxin (D2C7-IT) is a dual-specific recombinant immunotoxin comprising an EGFR-wt and mutant-specific (EGF ... Full text Cite

DDRE-20. GENERATION OF A HIGH-AFFINITY EGFR/EGFRvIII-TARGETED D2C7 CAR-T CELL

Conference Neuro-Oncology · November 9, 2020 AbstractBACKGROUNDThe intent of this investigation is to validate a novel, high-affinity epidermal growth factor receptor (EGFR) chime ... Full text Cite

QOLP-20. A FEASIBILITY STUDY UTILIZING MINDFULNESS MEDITATION DURING CONCOMITANT CHEMORADIATION IN MALIGNANT GLIOMA PATIENTS: HEALTH-REPORTED QUALITY OF LIFE (HRQOL) RESULTS

Conference Neuro-Oncology · November 9, 2020 AbstractBACKGROUNDPrimary brain tumor patients experience high levels of distress due to their diagnosis and treatment leading to chan ... Full text Cite

QOLP-29. MINDFULNESS MEDITATION PRACTICE IN MALIGNANT GLIOMA PATIENTS THROUGHOUT CONCOMITANT RADIATION AND TEMOZOLOMIDE: A FEASIBILITY STUDY

Conference Neuro-Oncology · November 11, 2019 AbstractWith a bleak prognosis for malignant glioma, maintaining quality of life (QoL) and decreasing distress of the patient are important in the clinical care of the patient. Mindfulness meditation is a mi ... Full text Link to item Cite

PDCT-10. FEASIBILITY OF LEUKAPHERESIS FOR HARVESTING MONOCYTES AND GENERATING AUTOLOGOUS DENDRITIC CELL VACCINES IN CHILDREN WITH MALIGNANT BRAIN TUMORS

Conference Neuro-Oncology · November 11, 2019 AbstractBACKGROUNDRecurrent medulloblastoma and malignant glioma are virtually incurable. In children, these tumors are often dissemin ... Full text Cite

QOLP-34. DOSE FREQUENCY MODIFICATION OF TRAMETINIB TO MITIGATE SEVERE RASH AND IMPROVE QUALITY OF LIFE IN PEDIATRIC LOW-GRADE GLIOMA PATIENTS

Conference Neuro-Oncology · November 11, 2019 AbstractCircumscribed low-grade glioma is generally driven by MAP kinase pathway activation, and this discovery motivates use of the non-competitive MEK 1/2 inhibitor trametinib for children and adults with ... Full text Cite

MEASURING ANTIBODY-SECRETING B-CELL RESPONSES TO IMMUNOLOGICAL STIMULI.

Conference Journal of Investigative Medicine · January 2007 Full text Cite

A Sheep in Wolf’s Clothing: An Atypical Etiology of a Cerebellar Lesion.

Conference nitial History/Presentation: A 12-year-old, previously healthy female presented with acute, intractable headaches. Headaches were preceded by one month of lethargy, myalgias, upper respiratory symptoms, and 8-pound weight loss. Symptoms rapidly progressed ... Cite

FIREFLY-1 (PNOC 026): A phase 2 study to evaluate the safety and efficacy of tovorafenib (DAY101) in pediatric patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors.

Conference Journal of Clinical Oncology FIREFLY-1 (PNOC 026): A phase 2 study to evaluate the safety and efficacy of tovorafenib (DAY101) in pediatric patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors. ... Full text Link to item Cite